Evidence map›Paper›PMID 38015242›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2024

Effects of different amosite preparations on macrophages, lung damages, and autoimmunity.

Alain Lescoat, Riccardo Leinardi, Kévin Pouxvielh, Yousof Yakoub, Marie Lelong, Amandine Pochet, Erwan Dumontet, Nessrine Bellamri, Erwan Le Tallec, Cristina Pavan and 4 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Alain LescoatUniv Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de Recherche en Santé, environnement et travail)-UMR_S 1085, 35000, Rennes, France.
Riccardo LeinardiLouvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale Et Clinique (IREC), Université Catholique de Louvain (UCL), Avenue Hippocrate 57, Bte B-1.57.06, 1200, Brussels, Belgium.
Kévin PouxvielhUniv Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de Recherche en Santé, environnement et travail)-UMR_S 1085, 35000, Rennes, France.
Yousof YakoubLouvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale Et Clinique (IREC), Université Catholique de Louvain (UCL), Avenue Hippocrate 57, Bte B-1.57.06, 1200, Brussels, Belgium.
Marie LelongUniv Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de Recherche en Santé, environnement et travail)-UMR_S 1085, 35000, Rennes, France.
Amandine PochetLouvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale Et Clinique (IREC), Université Catholique de Louvain (UCL), Avenue Hippocrate 57, Bte B-1.57.06, 1200, Brussels, Belgium.
Erwan DumontetCHU Rennes, Pôle de Biologie, Rennes, France.
Nessrine BellamriUniv Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de Recherche en Santé, environnement et travail)-UMR_S 1085, 35000, Rennes, France.
Erwan Le TallecUniv Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de Recherche en Santé, environnement et travail)-UMR_S 1085, 35000, Rennes, France.
Cristina Pavan"G. Scansetti" Interdepartmental Center for Studies On Asbestos and Other Toxic Particulates, University of Turin, Via Pietro Giuria 7, 10125, Turin, Italy.
Francesco Turci"G. Scansetti" Interdepartmental Center for Studies On Asbestos and Other Toxic Particulates, University of Turin, Via Pietro Giuria 7, 10125, Turin, Italy.
Christophe ParisUniv Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de Recherche en Santé, environnement et travail)-UMR_S 1085, 35000, Rennes, France.
François HuauxLouvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale Et Clinique (IREC), Université Catholique de Louvain (UCL), Avenue Hippocrate 57, Bte B-1.57.06, 1200, Brussels, Belgium.
Valérie LecureurUniv Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de Recherche en Santé, environnement et travail)-UMR_S 1085, 35000, Rennes, France. valerie.lecureur@univ-rennes.fr.ORCID 0000-0002-8606-4755
Inserm · FRUCLouvain · BEUniversity of Turin · ITCentre Hospitalier Universitaire de Rennes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The underlying mechanisms of asbestos-related autoimmunity are poorly understood. As the size, surface reactivity, and free radical activity of asbestos particles are considered crucial regarding the health effects, this study aims to compare the effects of exposure to pristine amosite (pAmo) or milled amosite (mAmo) particles on lung damage, autoimmunity, and macrophage phenotype. Four months after lung exposure to 0.1 mg of amosite, BAL levels of lactate dehydrogenase, protein, free DNA, CCL2, TGF-β1, TIMP-1, and immunoglobulin A of pAmo-exposed C57Bl/6 mice were increased when compared to fluids from control- and mAmo-exposed mice. Effects in pAmo-exposed mice were associated with lung fibrosis and autoimmunity including anti-double-strand DNA autoantibody production. mAmo or pAmo at 20 µg/cm

Indexed as

Asbestos, AmositePulmonary FibrosisAnimalsAutoimmunityDNAHumansInterleukin-6LungMacrophagesMiceAsbestos, AmositeDNAInterleukin-6Amosite fibersAutoimmunityEfferocytosisLung fibrosisMacrophages

Identifiers

PMID38015242
OpenAlexW4389083567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.